Yes, metoprolol can cause erectile dysfunction, and the effect is most plausible with the succinate (extended-release) formulation at higher doses. The best-attributed risk comes from the 2007 ONTARGET trial, which reported roughly 13-14% erectile dysfunction incidence with metoprolol succinate versus about 8% with the comparison drug. The problem is dose- and formulation-dependent rather than universal.

Metoprolol sits in the beta-blocker class, a group long associated with sexual side effects. That association is partly real physiology and partly the residue of older, flawed study designs. Separating the two matters because metoprolol remains one of the most prescribed beta-blockers in the United States.

Why Beta-Blockade Reaches the Penis

An erection is a vascular event triggered by neural signaling. Parasympathetic nerves release nitric oxide, which relaxes the smooth muscle lining the penile arteries. Blood floods the corpora cavernosa, and the resulting pressure compresses the veins that would otherwise drain it. Any drug that interferes with that sequence, or with the blood pressure and cardiac output driving it, can blunt the response.

Metoprolol is a cardioselective beta-1 antagonist. In theory, selectivity should spare beta-2 receptors, which matter for peripheral vasodilation. In practice, selectivity is dose-dependent and fades at higher doses. The drug slows heart rate and lowers cardiac output, which can reduce the pulsatile pressure that helps drive penile blood flow. It also lowers blood pressure itself, and a lower perfusion gradient makes achieving and sustaining rigidity harder.

The deeper mechanism is biochemical. Beta-blockade can reduce nitric oxide bioavailability and shift the balance toward vasoconstrictive signaling. Metoprolol does not act on alpha receptors directly, so it produces less erectile dysfunction than nonselective agents like propranolol or the alpha-blocking labetalol. That relative gentility is real but partial. The drug's effect on libido is a separate question: fatigue, reduced exercise tolerance, and depressed mood can all lower sexual interest independently of vascular function.

Plain language: the drug can weaken the hydraulic signal and the pressure behind it without ever touching the hormone system directly.

How Large Is the Metoprolol Effect?

Quantifying beta-blocker sexual side effects is harder than it sounds, because early studies used leading questions and uncontrolled designs. The most cited modern estimate comes from ONTARGET, a large cardiovascular outcomes trial that captured adverse events systematically. In that trial, metoprolol succinate was associated with erectile dysfunction in roughly 13-14% of men, compared with about 8% on the comparator.

That gap, roughly 5-6 percentage points, is the most defensible attributable risk figure available for metoprolol specifically. It is not a universal constant. It reflects a particular population (high cardiovascular risk), a particular formulation (extended-release succinate), and a particular dosing range.

A separate reality: erectile dysfunction is common in the exact population that takes metoprolol. Hypertension, diabetes, dyslipidemia, smoking, and atherosclerosis all independently impair erectile function. In many men, the underlying vascular disease would have produced erectile dysfunction with or without the drug. Attribution requires a temporal link, a dose relationship, and improvement on withdrawal, and most clinical encounters capture none of these cleanly.

Formulation matters in ways the trials did not always separate. Immediate-release tartrate is taken multiple times daily and produces sharper peak-trough swings. Extended-release succinate is smoother. Whether that translates to meaningfully different erectile outcomes is not settled by head-to-head data.

When the Risk Bites Hardest

Risk is not uniform across men. Several edges sharpen it.

Higher doses: cardioselectivity erodes as dose climbs, and beta-2 spillover increases with it. Pre-existing endothelial dysfunction: men with diabetes or established atherosclerosis have less vascular reserve to lose. Polypharmacy: thiazide diuretics and older-generation beta-blockers add independent sexual side effects that compound. Age and baseline function: a man with marginal erectile function has less room to absorb any decrement. Depression or fatigue on the drug: mood and energy effects can suppress libido without any vascular component.

A counterintuitive professional caveat: the beta-blocker with the worst sexual side effect reputation, propranolol, is nonselective, yet some evidence suggests nebivolol, a beta-1 selective agent with nitric-oxide-mediated vasodilation, has among the lowest rates in the class. Class labels obscure real differences between agents, and metoprolol's position within that spectrum is intermediate, not extreme.

Red-flag warnings worth knowing:

New erectile dysfunction accompanied by chest pain on exertion suggests cardiac ischemia and warrants urgent evaluation, not a medication change. Erectile dysfunction plus loss of morning erections and low libido points toward a hormonal or vascular cause beyond the drug. Abruptly stopping metoprolol to test the hypothesis can trigger rebound tachycardia and angina. Never do this without a clinician. Erectile dysfunction that persists for months after discontinuation argues against the drug as the sole cause.

Misconceptions Worth Retiring

The most persistent misconception is that beta-blockers uniformly destroy sexual function. The data do not support uniformity. Metoprolol's attributable risk in the best available trial is modest, in the range of a few percentage points, and many men tolerate it without sexual change.

A second misconception is that the effect is purely psychological. Some of it may be: the expectation of sexual side effects is well documented for many drug classes, and beta-blocker studies that asked directly about sexual function found higher rates than those relying on spontaneous reporting. But the ONTARGET signal was captured through systematic adverse-event collection, which weakens the pure-expectation explanation.

A third misconception confuses erection with libido. Metoprolol's vascular effects bear on erection quality. Its fatigue and mood effects bear on desire. These are separable problems with separable fixes, and treating them as one entity leads to the wrong intervention.

A fourth misconception is that switching to another beta-blocker solves everything. Switching may help if the dose was high or the agent nonselective. It may do nothing if the underlying vascular disease is the real driver. The only way to know is a structured trial, not a guess.

Comparison of Antihypertensive Classes and Sexual Side Effects

Drug or class Typical erectile dysfunction signal Mechanism relevant to sexual function
Metoprolol succinate Modest, roughly 13-14% in ONTARGET vs 8% comparator Beta-1 blockade, reduced cardiac output, some nitric oxide reduction
Propranolol Higher than cardioselective agents Nonselective beta blockade, broader vascular effects
Nebivolol Among the lowest in beta-blocker class Beta-1 selective with nitric-oxide-mediated vasodilation
Thiazide diuretics Low to moderate Volume and electrolyte effects, indirect vascular impact
ACE inhibitors Low Favorable vascular remodeling, neutral to modest benefit
Angiotensin receptor blockers Low Similar to ACE inhibitors, neutral to modest benefit
Calcium channel blockers Low Vasodilation without beta blockade

This table compares directional signals, not head-to-head trial results. The honest reading is that beta-blockers as a class carry more sexual side-effect signal than renin-angiotensin agents, and metoprolol sits in the middle of its class rather than at the worst end.

Timeline: What to Expect and When

Time frame What typically happens
First 1-2 weeks Blood pressure and heart rate stabilize; sexual effects, if any, may not yet be apparent
Weeks 2-8 Most drug-attributable sexual side effects, if they occur, become noticeable
Months 2-6 Effects plateau; improvement without dose change is uncommon but possible
After dose reduction Improvement within days to weeks if the drug is the cause
After discontinuation Improvement within 1-4 weeks if drug-attributable; persistence beyond that suggests another cause
After switching agents Reassessment at 4-8 weeks on the new agent
Long term Underlying vascular disease may progress independent of the drug

The timeline is the diagnostic tool. A side effect that appears within weeks of starting or dose escalation and resolves within weeks of stopping has a plausible causal link. One that appears years later, or persists after withdrawal, does not.

Practical Actions and Thresholds

The first step is documentation, not speculation. Track erectile function before and after any dose change using a validated instrument such as the IIEF-5, and note morning erections, libido, and fatigue separately. A clinician cannot act on a vague complaint but can act on a pattern.

The second step is a structured trial. If the drug is suspected, a clinician may reduce the dose or switch to an agent with a more favorable profile, such as nebivolol or a renin-angiotensin agent, while monitoring blood pressure. This is a clinical decision, not a self-directed experiment. Do not stop metoprolol abruptly.

The third step is to address confounders in parallel. Blood pressure control, glucose control, smoking cessation, weight, and sleep apnea all affect erectile function. Fixing the drug while ignoring these yields partial answers.

A practical threshold: if erectile dysfunction persists for more than 3 months after a supervised switch away from metoprolol, the drug is unlikely to be the primary cause and a vascular or hormonal workup is warranted. If it improves within 4-8 weeks of the switch, the drug was likely contributory.

Limits of the Evidence

The honest answer to the question is bounded by what the data can support. ONTARGET provides the strongest quantified signal, but it was not designed as a sexual-function trial, and its erectile dysfunction rates came from adverse-event reporting rather than validated questionnaires. Smaller studies using validated instruments exist but are inconsistent in dose, formulation, and population.

Formulation-specific data are thin. Whether metoprolol tartrate and succinate differ meaningfully in erectile outcomes has not been settled by adequately powered head-to-head trials. Dose-response data are similarly incomplete, though the mechanistic expectation of worsening at higher doses is reasonable.

Confounding is the deepest limitation. The men who take metoprolol are the men most likely to have erectile dysfunction for reasons unrelated to the drug. Without a washout trial in an individual patient, causality at the individual level remains an inference, not a certainty.

What can be said with confidence: metoprolol can cause erectile dysfunction, the attributable risk is modest and dose-dependent, the effect is reversible in many cases, and the drug is neither the most nor the least problematic option in its class. The remaining uncertainty is not about whether the effect exists but about how large it is in any given man, which is a question only a structured personal trial can answer.